Biomea Fusion Inc Total Liabilities
Biomea Fusion Inc total liabilities. Based on the latest financial reports, Biomea Fusion Inc (BMEA) has total liabilities worth $27.67 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BMEA financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biomea Fusion Inc (2019–2025)
Total liabilities of Biomea Fusion Inc from 2019 to 2025. This chart illustrates how Biomea Fusion Inc's total liabilities have evolved over time, based on quarterly financial data. Explore BMEA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Biomea Fusion Inc Competitors by Total Liabilities
The table below lists competitors of Biomea Fusion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sigong Tech Co. Ltd
KQ:020710
|
Korea | ₩64.86 Billion |
|
Walkabout Resources Ltd
AU:WKT
|
Australia | AU$36.64 Million |
|
InkTec Co. Ltd
KQ:049550
|
Korea | ₩79.82 Billion |
|
Hofseth Biocare ASA
OL:HBC
|
Norway | Nkr419.19 Million |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
China | CN¥2.84 Billion |
|
Iskandar Waterfront City Bhd
KLSE:1589
|
Malaysia | RM636.26 Million |
|
Immutep Limited
F:YP1A
|
Germany | €48.30 Million |
|
PEH Wertpapier AG
F:PEH
|
Germany | €28.76 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Biomea Fusion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BMEA total asset value.
Liquidity & Leverage Metrics
Biomea Fusion Inc Total Liabilities Ratios Explained
Biomea Fusion Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomea Fusion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomea Fusion Inc (2019–2025)
The table below shows the annual total liabilities of Biomea Fusion Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.02 Million | +2.31% |
| 2024-12-31 | $28.36 Million | -7.58% |
| 2023-12-31 | $30.69 Million | +47.78% |
| 2022-12-31 | $20.77 Million | +200.03% |
| 2021-12-31 | $6.92 Million | -87.93% |
| 2020-12-31 | $57.36 Million | +19954.90% |
| 2019-12-31 | $286.00K | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more